Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.2B
48M shares
52-week range
$51.91 – $81.95
54% from low
Sector
SERVICES-MANAGEMENT CONSULTING SERVICES
Exchange
NASDAQ
CS
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
www.exponent.comNo one on the platform currently holds EXPO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 88,000 | $5.7M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-04 | $0.3100 | 2026-09-18 |
| 2026-06-05 | $0.3100 | 2026-06-18 |
| 2026-03-06 | $0.3100 | 2026-03-20 |
| 2025-12-05 | $0.3000 | 2025-12-19 |
| 2025-09-05 | $0.3000 | 2025-09-19 |
| 2025-06-06 | $0.3000 | 2025-06-20 |
| 2025-03-07 | $0.3000 | 2025-03-21 |
| 2024-12-06 | $0.2800 | 2024-12-20 |
| 2024-09-06 | $0.2800 | 2024-09-20 |
| 2024-06-07 | $0.2800 | 2024-06-21 |
No one on the platform has traded EXPO yet.
| 2024-03-07 | $0.2800 | 2024-03-22 |
| 2023-12-07 | $0.2600 | 2023-12-22 |
| Execution date | Ratio |
|---|---|
| 2018-06-08 | 2-for-1 |
| 2015-06-05 | 2-for-1 |
| 2006-06-12 | 2-for-1 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $587M | +9.7% | $2.30 | $2.28–$2.31 | 29.7× | 3 |
| 2028 | $635M | +8.1% | $2.60 | $2.58–$2.61 | 26.2× | 3 |
| 2029 | $679M | +6.8% | $2.82 | $2.81–$2.82 | 24.2× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.55 | $0.60 | +9.3% |
| 2026-04-30 | $0.56 | $0.59 | +5.4% |
| 2026-02-05 | $0.47 | $0.49 | +4.3% |
| 2025-10-30 | $0.50 | $0.55 | +10.0% |
| 2025-07-31 | $0.48 | $0.52 | +8.3% |
| 2025-05-01 | $0.48 | $0.52 | +8.3% |
| 2025-02-06 | $0.40 | $0.46 | +15.0% |
| 2024-10-24 | $0.48 | $0.50 | +4.2% |
| $3.0B |
| — |
| HAYWHayward Holdings, Inc. | $15.29 | -0.07% | $3.2B | — |
| HURNHuron Consulting Group Inc. | $155.31 | +3.33% | $2.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
$EXPO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.60 up 15.38% YoY • Reported revenue of $171.61M up 20.89% YoY • Exponent anticipates third quarter 2026 revenues before reimbursements to grow 8% to 10% and EBITDA to be 28.0% to 28.5%, while raising full-year 2026 guidance to 9% to 10% revenue growth.
View on StockTwits ↗Wall St is expecting 0.59 EPS for $EXPO Q3 [Reporting 10/22 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗The rankings today, 7/23/2006 LONG BONDS $EDV COMMUNICATIONS $EXPO GOLD $GLDM HEALTH $IHI INTERMEDIATE BONDS $FBND
View on StockTwits ↗Hey $APPS folks, I believe the future looks bright for the company, and those who’ve been here from the start have seen some incredible returns. Lately, my focus in small caps has been on $EXPO and $VIAV. What do you think? Has anyone checked them out?
View on StockTwits ↗Wall St is expecting 0.55 EPS for $EXPO Q2 [Reporting 07/23 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗Wall St is expecting 0.55 EPS for $EXPO Q2 [Reporting 07/23 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗Wall St is expecting 0.55 EPS for $EXPO Q2 [Reporting 07/23 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗Exponent: Rising Demand And A Reasonable Valuation Make It A Buy $EXPO https://seekingalpha.com/article/4897939-exponent-stock-rising-demand-and-a-reasonable-valuation-make-it-a-buy
View on StockTwits ↗$EXPO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.59 up 13.46% YoY • Reported revenue of $166.3M up 14.29% YoY • For the second quarter of fiscal 2026, Exponent anticipates revenues before reimbursements to grow in high-single digits and EBITDA to be 27.0% to 27.8% of revenues before reimbursements. Exponent maintains this guidance for the full fiscal year 2026.
View on StockTwits ↗Wall St is expecting 0.57 EPS for $EXPO Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗Wall St is expecting 0.57 EPS for $EXPO Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/expo?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$EXPO Share Price: $66.55 Contract Selected: Sep 18, 2026 $65 Calls Buy Zone: $4.67 – $5.78 Target Zone: $8.90 – $10.87 Potential Upside: 80% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$EXPO leadership changes announced — stock at $66.56, market cap $3.3B. The filing does not specify any named successors for the leadership roles. Leadership vacuum without clear successors may lead to short-term volatility.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.